Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAt Creative Biolabs, we believe that species selection isn't just a biological variable—it's a strategic advantage. In recent years, dogs have emerged as a powerful and underutilized host species for monoclonal antibody discovery, particularly when it comes to generating antibodies against canine-relevant antigens, large proteins, and complex conformational structures.
The diverse immune repertoire and robust antibody responses of dogs make them particularly valuable for generating antibodies that are challenging to obtain from traditional models such as mice or rabbits. Creative Biolabs' Canine Monoclonal Antibody Discovery Service, powered by our proprietary phage display technology, offers new opportunities for researchers in therapeutic development and advanced diagnostics. It is especially well-suited for the development of pet/animal-related drugs, including those targeting cats and dogs.
Creative Biolabs provides a complete, customizable pipeline for canine-derived monoclonal antibodies. Whether you need early-stage binder identification or full recombinant antibody production with engineering, we can support your program at every level.
Our core canine antibody discovery services include:
Creative Biolabs' scientific staff works hand-in-hand with you to ensure your specific goals are not just met—but exceeded.
At Creative Biolabs, we recognize that no single approach fits every research goal. That's why we offer two scientifically rigorous, complementary workflows to discover high-quality monoclonal antibodies suitable for canine applications:
① one based on direct canine immunization and phage display screening, and
② another using murine hybridoma-derived antibodies followed by canine-specific engineering.
These dual paths allow our clients to choose the most appropriate method depending on antigen complexity, downstream application, and available pre-existing reagents.
Our scientific team begins with a deep-dive consultation to assess your antigen, the desired application (e.g., research, diagnostic, or therapeutic), and your preferred host strategy. Based on this, we recommend either:
We'll tailor the optimal path—or combine both—for your specific goals.
Our antigen services include:
The antigen format is optimized for high immunogenicity and epitope preservation in dogs.
We follow proprietary immunization protocols to stimulate strong B-cell responses in dogs. Titer assessments guide timing of PBMC harvest.
Alternatively, we offer naïve or synthetic canine libraries for non-immunization-based approaches.
From dog PBMCs or synthetic sequences, we construct scFv or Fab phage libraries with high CDR diversity. These libraries are the foundation for downstream screening.
Using multiple rounds of biopanning and stringent selection, we isolate high-affinity, target-specific antibodies.
Positive clones undergo:
We use our NGS platform for lineage mapping and diversity assessment.
We express and optionally engineer the validated clones (e.g., affinity maturation, Fc customization, or therapeutic formatting). Outputs can include scFv, IgG, bispecific, etc.
This approach is particularly useful when:
We immunize mice with your antigen and fuse B cells with myeloma lines to generate stable hybridoma clones.
We extract VH/VL regions from validated mouse hybridomas for further engineering.
Mouse-derived antibody sequences are reformatted into canine-compatible frameworks, preserving antigen binding while reducing immunogenicity in dogs. This process parallels traditional humanization but uses canine IgG constant and variable region scaffolds.
Engineered caninized antibodies are recombinantly expressed and validated for: Retained binding, Reduced immunogenicity, in vivo stability and pharmacokinetics (optional).
This approach is ideal for adapting existing antibodies for use in canine diagnostics, therapy, or veterinary biologics.
When your project concludes, Creative Biolabs provides a full suite of materials and data, including:
We also offer ongoing support for downstream integration, licensing, or scale-up manufacturing.
| Case Study A: Direct Canine-Derived Antibody via Phage Display Platform | |||||||
 Robust Immune Response Induced by Canine Immunization |
Construction of Immune Canine Antibody Library |
||||||
 Positive Enrichment Post-Screening Against Target Protein |
 Identification of Strong Binders to Target Protein in Subsequent Validation |
||||||
| Results: We successfully obtained suitable positive clones through Path A (immunization + phage display platform), facilitating downstream identification and engineering for our client. | |||||||
| Case Study B: From Murine Antibody to Canine Antibody by In Silico Caninization | |
 Strong Immune Response Induced by Mouse Immunization |
 Isolation of Stable Positive Clones Through Hybridoma Screening |
 Recombinant Mouse Antibodies Demonstrating Positive Binding to Target |
 High Affinity Binding Retained After In Silico Caninization |
| Results: We generated positive clones through hybridoma screening and selected the top candidate for in silico canineization. After choosing and optimizing the most appropriate canine framework, we identified several caninized antibody candidates. Three of these candidates were expressed and showed high affinity binding to the antigen, with activities slightly lower than that of the mouse antibody. | |
At Creative Biolabs, we've built an advanced infrastructure to ensure quality, reproducibility, and innovation across all our antibody discovery services.
Here's why Creative Biolabs is the preferred partner for academic labs, biotech startups, and global pharmaceutical companies:
"Creative Biolabs was the first CRO we found offering a canine mAb service using phage display. Their ability to navigate our complex membrane target and deliver specific binders was nothing short of impressive."
— Senior Researcher, Germany
"We appreciated the transparency and communication throughout. Creative Biolabs helped us explore canine models when everything else failed. We'll definitely use them again for future diagnostics projects."
— Director of R&D, Canada
If you're facing challenges in monoclonal antibody discovery—or simply looking for a fresh, species-informed approach—Creative Biolabs Canine Monoclonal Antibody Discovery Service is ready to deliver. Contact us today to explore your options, receive a tailored proposal, or discuss feasibility with our scientific experts.
Our extensive expertise covers a variety of host species, including goats, ferrets, hamsters, dogs, guinea pigs, alligators, and more—demonstrating our adaptable, model-driven approach tailored to the unique needs of each antibody project.
A: Dogs offer a broader immune repertoire compared to rodents and can generate antibodies against targets that are poorly immunogenic in mice or rats, including highly conserved human proteins and large complex antigens.
A: After immunizing dogs and isolating B cells, we amplify VH/VL regions, clone them into phage display vectors (e.g., scFv), and construct a high-diversity phage library for screening.
A: No, Creative Biolabs offers antigen design and preparation services. You're also welcome to provide your antigen material if preferred.
A: Timelines vary, but full projects (immunization to validated clones) typically range from 24 to 32 weeks. Naïve or synthetic libraries may require slightly less time.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
